LMO7, a protein encoded by the LMO7 gene, plays a significant role in various cancers. It is involved in cell adhesion, cytoskeletal organization, and signaling pathways, and has been implicated as an oncogene in several types of cancer. LMO7's expression is associated with aggressive cancer phenotypes, increased cell migration, and poor patient prognosis. It regulates the expression of genes involved in myogenesis and influences cancer cell migration and invasion through interactions with various proteins, including those involved in the actin cytoskeleton and focal adhesion complexes. LMO7 also promotes epithelial-mesenchymal transition (EMT), which is crucial for cancer progression. It interacts with signaling pathways such as PI3K/AKT/mTOR, Rho-GTPase, and ERK/MAPK, contributing to cell survival, proliferation, and metastasis. Additionally, LMO7 is involved in epigenetic modifications, including DNA methylation, which can affect its expression and function in cancer. LMO7's expression varies across different cancer types, with some showing upregulation and others downregulation. It has prognostic significance in several cancers, including breast, lung, and pancreatic cancers. LMO7 mutations and genomic alterations, such as amplification, deep deletion, and structural variants, are observed in various cancers, suggesting its role in cancer development. Despite its potential as a therapeutic target, challenges remain in understanding its precise molecular mechanisms and developing specific inhibitors. Further research is needed to fully elucidate LMO7's role in cancer and to explore its potential as a therapeutic target and prognostic marker.LMO7, a protein encoded by the LMO7 gene, plays a significant role in various cancers. It is involved in cell adhesion, cytoskeletal organization, and signaling pathways, and has been implicated as an oncogene in several types of cancer. LMO7's expression is associated with aggressive cancer phenotypes, increased cell migration, and poor patient prognosis. It regulates the expression of genes involved in myogenesis and influences cancer cell migration and invasion through interactions with various proteins, including those involved in the actin cytoskeleton and focal adhesion complexes. LMO7 also promotes epithelial-mesenchymal transition (EMT), which is crucial for cancer progression. It interacts with signaling pathways such as PI3K/AKT/mTOR, Rho-GTPase, and ERK/MAPK, contributing to cell survival, proliferation, and metastasis. Additionally, LMO7 is involved in epigenetic modifications, including DNA methylation, which can affect its expression and function in cancer. LMO7's expression varies across different cancer types, with some showing upregulation and others downregulation. It has prognostic significance in several cancers, including breast, lung, and pancreatic cancers. LMO7 mutations and genomic alterations, such as amplification, deep deletion, and structural variants, are observed in various cancers, suggesting its role in cancer development. Despite its potential as a therapeutic target, challenges remain in understanding its precise molecular mechanisms and developing specific inhibitors. Further research is needed to fully elucidate LMO7's role in cancer and to explore its potential as a therapeutic target and prognostic marker.